AssetMark Inc’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

AssetMark Inc’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-73	Closed	-$3K	–	1462
2016 Q4	$3K	Buy	+73	New	+$2.97K	﹤0.01%	1105

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AssetMark Inc's XPH Position: Q1 2017 in Review

AssetMark Inc sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2017, closing a stake of 73 shares — an estimated $3K sold.

AssetMark Inc first reported a position in XPH in Q4 2016 and held it in 1 quarter. The position peaked at $3K in Q4 2016. 79 funds tracked by Wall St. Rank hold XPH as of Q1 2017.

AssetMark Inc reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2017 after selling out during the quarter.
AssetMark Inc sold 73 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2017, an estimated $3K.
AssetMark Inc first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and held it in 1 quarter.
AssetMark Inc's State Street SPDR S&P Pharmaceuticals ETF position peaked at $3K in Q4 2016.
79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2017.

Based on AssetMark Inc's 13F filing for Q1 2017, filed 9 May 2017.